Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer
Go back to Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 -1.27 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.09 | 52 Week High | $77.12 | |||
| Open | $67.24 | 52 Week Low | $49.03 | |||
| Day High | $67.72 | P/E | 43.39 | |||
| Day Low | $66.58 | EPS | $1.54 | |||
| Volume | 4,825,448 | |||||
